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Abstract 
 
Background  
Work-related cancer is an important public health issue with a large financial impact on 
society. The key European legislative instrument is the Carcinogens and Mutagens 
Directive (2004/37/EC). In preparation for updating the Directive the European 
Commission commissioned a study to provide a socioeconomic, health and 
environmental impact assessment.  
 
Methods 
The evaluation was undertaken for 25 pre-selected hazardous substances or mixtures. 
Estimates were made of the number of cases of cancer attributable to workplace 
exposure, both currently and in the future, with and without any regulatory 
interventions, and these data were used to estimate the financial health costs and 
benefits.   
 
Results 
It was estimated that if no action is taken there will be more than 700,000 attributable cancer 
deaths over the next 60 years for the substances assessed. However, there are only seven 
substances where the data suggests a clear benefit in terms of avoided cancer cases from 
introducing a binding limit at the levels considered. Overall, the costs of the proposed 
interventions were very high (up to €34,000m) and the associated monetised health benefits 
were mostly less than the compliance costs. 
 
Conclusions 
The strongest cases for the introduction of a limit value are for: respirable crystalline 
silica, hexavalent chromium and hardwood dust.  
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Introduction  
There are more than 3 million cancers recorded in the European Union each year and 
about 1.7 million cancer deaths, predominantly lung, colorectal, breast and stomach 
cancer (Ferlay et al, 2007). Recent research in Britain has shown that approximately one 
in twenty cancer deaths may be attributable to work (about 8% in men and 2% in 
women), with mesothelioma, sinonasal, lung, nasopharyngeal and breast cancer in 
women having the greatest proportion of cases due to work (Rushton et al, 2012). The 
main agents contributing to the workplace cancer burden in Britain are asbestos, shift-
work involving night work, mineral oils, solar radiation, silica, diesel engine exhaust, 
coal tars and pitches, occupation as a painter or welder, dioxins, environmental tobacco 
smoke, radon, tetrachloroethylene, arsenic and strong inorganic acid mists. Purdue et al 
(2015) reviewed published reports with quantitative estimates of the population 
attributable fraction for all cancer from occupational exposures. Estimates ranged 
between 2% and 8%, with the values for men ranging 3-14% and for women from 1-2%.  
The highest estimate was from Finland: 14%, men and 2%, women (Nurminen & 
Karjalainen, 2001).  
 
In Europe, Directive 2004/37/EC on the Protection of Workers from the Risks Related 
to Exposure to Carcinogens or Mutagens at Work (the Carcinogens Directive), provides a 
common legislative framework for managing occupational cancer risks1. The Directive 
sets out general strategies for workplace risk management and includes requirements 
for assessment of risks, prevention or reduction of exposure and other elements of a risk 
management strategy. The scope includes supplied substances classified as category 1a 
or 1b carcinogens under the European Classification, Labelling and Packaging (CLP) 
Regulations (European Regulation (EC) No 1272/2008), but at the moment does not 
                                                        
1 The Directive was amended in 2014 (2014/27/EC) in order to align them to 
Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances 
and mixtures. 
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include most process-generated carcinogenic substances such as diesel engine exhaust 
or crystalline silica. In addition, there are currently only three carcinogenic agents with 
specified occupational exposure limits (benzene, vinyl chloride monomer and inhalable 
hardwood dust). Each European country implements the Directive into their national 
law.  
 
The European Commission DG Employment, Social Affairs, Inclusion (DG EMPL) is in the 
process of updating the Carcinogens Directive to address some of the perceived 
limitations and to extend the scope to include additional substances. As part of this work 
we have undertaken a socioeconomic, health and environmental analysis of possible 
changes to the Carcinogens Directive for 25 occupational carcinogenic substances 
identified by DG EMPL for possible inclusion in a revision to the Directive (Table 1).  In 
particular we assessed the potential impact of introducing legally binding occupational 
exposure limits (OELs), specified as 8-hour Time Weighted Average (TWA) air 
concentrations.  This paper summarises the methodology and main results from the 
health and economic  assessments, which was the main focus for the work. The detailed 
reports from the project, including the more limited social and environmental 
assessments, are available and can be found on the European Commission website 
(http://ec.europa.eu/social/keyDocuments.jsp?advSearchKey=IOM&mode=adva
ncedSubmit&langId=en&search.x=10&search.y=5 ).  
 
Methods  
Overview 
The burden of cancer due to past and predicted future occupational use of the 25 
carcinogens (note, rubber process dust and fume were evaluated separately) was 
estimated using the general methodology developed for the British burden of 
occupational cancer study (Rushton et al, 2012). The health costs of these cancers were 
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then estimated assuming (i) that no changes in exposure occurred (baseline), and (ii) for 
intervention scenarios in which OELs are introduced or existing OELs in the Directive 
are reduced.  OEL values were either suggested by the European Commission or were 
identified as being “typical” of values in EU member states. For some carcinogens up to 
three different OELs were separately assessed. Costs to industry of compliance with the 
new OEL values were also estimated for each intervention scenario.  This enabled the 
costs and benefits of the “do nothing” scenario to be compared with the intervention 
scenarios. 
 
Exposure Data 
Information about the uses and/or circumstances of exposure for each substance, 
together with additional information provided by stakeholders was used to assess the 
exposures in the European working population. The main sources of information to 
estimate prevalence of exposure were: 
• Labour Force Survey (LFS) and EU wide structural business statistics (SBS) data 
from EUROSTAT (http://ec.europa.eu/eurostat/help/new-eurostat-website);  
• CAREX for 15 EU countries (1993), updated in Finland for 2000 and 2007, in Spain 
and in Italy for the period 2000 – 2003 (Kogevinas et al, 2000; Mirabelli & 
Kauppinen, 2005); 
• WOODEX – database with estimates of prevalence and levels of wood dust 
exposure for 25 EU countries by industry (Kauppinen et al, 2006); and  
• Information from stakeholders such as trade associations. 
 
Exposure prevalence data were available from CAREX for all the agents with the 
exception of: rubber fumes and dust, mineral oils as used engine oils, 1,2-epoxypropane, 
1-chloro-2,3-epoxypropane, 2-nitropropane and 4,4'-methylenedianiline. Exposure 
prevalence for rubber fumes and dust exposure was estimated from the SBS data. 
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Exposure prevalence for the remaining agents came from information collected from 
trade associations and other stakeholders. The information from CAREX and other 
sources, were combined with data from EUROSTAT to obtain estimates of exposure 
prevalence. 
 
The level or intensity of exposure was assessed using: 
• published scientific literature; 
• information from European Risk Assessment Reports compiled in relation to the 
EU Existing Substances Regulations; 
• the Woodex database for hardwood dust; 
• the Exasrub database for rubber dust (de Vocht, 2005); 
• information provided by industry stakeholders. 
 
Temporal changes in exposure were determined using information from the literature, 
which was ideally specific to the substance being considered but in situations where this 
was not available, and it was our view that there was a decline in exposure levels over 
time, we relied on the results from a systematic review of the literature (Creely, et al. 
2007). 
 
Statistical methods 
The statistical methodology for estimating the burden of occupational cancer was based 
on that developed for the British occupational cancer study (Hutchings & Rushton 
2012a). Levin’s formula was used to estimate the attributable fraction (AF), i.e. the 
proportion of cases due to occupational exposure. This requires an estimate of the risk 
of disease, e.g. relative risk (RR), obtained from published literature and the proportion 
of the population exposed, derived from data sources described above, while accounting 
for employment turnover and life expectancy, and adjusted for employment trends. A 
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Risk Exposure Period (REP) was defined as the relevant exposure period accounting for 
cancer latency (10-50 years for solid tumours, 0-20 years for blood cancers). RRs were 
selected for ‘high’ and ‘low’ exposure levels and industries were allocated accordingly. 
 
For predicting future burden, the risk exposure windows were projected forward in 
time, and estimation was carried out for a series of forecast target years (FTYs) that 
stretch far enough into the future to account for the latency of cancers currently being 
initiated, i.e. to the decade starting 2060 (Hutchings & Rushton, 2012b). The method 
enables predictions to be made for a range of alternative scenarios of change for 
example, reducing exposure limits or improvement in compliance. For this study the 
European Commission asked us to investigate introduction in 2010 of new OELs or the 
reduction of existing exposure limits for the substances, and to assume that there would 
be “full compliance” with the OEL from the date it was introduced, i.e. that more than 
99% of exposures in the EU would be less than the limit value. Where a substance was 
banned or usage had been restricted in the past then these changes were reflected in the 
exposure prevalence data used for estimation of future burden. 
 
Projected changes in the number of exposed workers were based on historic changes in 
the numbers employed in grouped main industry sectors from the EU LFS. Projections of 
cancer deaths and registrations for the forecast target years were based on current rates 
(2006 for deaths, generally 2002 for registrations) applied to EU country specific 
population projections by age. Trends in employment and exposure were applied until 
2030 and remained steady thereafter. 
 
Results from projections in the future, based on the pattern of past and current 
exposure and intervention scenarios, were compared with a baseline scenario that 
assumes no change in exposed numbers or exposed levels beyond 2010, to assess 
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relative impact on reducing attributable numbers of cancers. We calculated the number 
of avoided cases as a consequence of introducing the proposed OELs. For used mineral 
oils, where there was no proposed OEL, no assessment was made of avoided cases.  
 
Costs were based on estimated cancer registrations and associated disability-adjusted 
life-years (DALYs). DALYs are calculated as the sum of the years of life lost due to 
premature mortality (YLLs) and the years lost due to disability (YLDs), reflected in a 
Cost of Illness (COI) or willingness-to-pay (WTP) to avoid the suffering and 
inconvenience of disease. One DALY represents one year of healthy life lost through 
early death or living with a disability. The costs of health impacts were estimated for:  
1. the Value of  Life Years Lost (VLYL) by multiplying the YLLs by an estimate of the 
Value of Life Year Lost (VLYL); €50,000 was used for the minimum VLYL and 
€100,000 for the maximum (European Commission, 2009). 
2. the COI; this includes the direct (such as inpatient, outpatient home care), 
indirect (such as loss of income) and intangible costs (disfigurement, functional 
limitations). 
Further discussion of the cost estimates used in this study can be found in the online 
material. 
 
Information required for the estimation of the COI for each type of cancer is scarce and 
therefore has been taken from existing studies related to cancer. Rabl (2004) provides 
values of unit costs (i.e. per patient) that are used in France for different morbidity risks, 
and includes estimates for COI and WTP. Their estimate (€ 48,600) has thus been used 
for all cancers. Future health costs were discounted at the same annual rate (4%) as 
compliance cost estimates. Sensitivity analysis was carried out using both a declining 
discount rate and no discounting. Since the health impacts occur over a long period of 
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time relative to compliance costs the impacts of discounting can have a significant 
impact on the overall size of the monetised health benefits.  
 
We considered the compliance costs of meeting the proposed amendments to the 
Directive, particularly the introduction of a limit value. To do this we identified the main 
uses leading to exposures that are in excess of the proposed OEL and the industry 
sectors in which those uses take place. Minor uses were considered but not assessed in 
detail. Information sources on likely compliance costs were limited. For example, in 
relation to hard wood dust we relied on a report from a campaign by the French 
Ministry of Labour, which involved around 3,100 visits to wood working sites, 
supplemented by attempts to obtain information from relevant trade associations and 
ventilation suppliers. 
 
Consideration was given to the possible risk management measures (RMM) that may be 
applied in order to meet the investigated OEL and whether these RMM may have already 
been applied – in some countries or all EU countries. Background information on all 
agents in the project were obtained from published literature and stakeholder contacts 
to identify: 
• the uses and activities that lead to workplace exposure; 
• the structure of the sectors in which exposure occurs: (e.g. numbers employed 
demographics of employees and geographical distribution of firms in the EU); 
• exposure control measures currently in place, available and required to meet the 
proposed OEL; and 
• the possible costs of exposure control measures. 
 
In order to understand the economic impacts on sectors in which specific uses cause a 
risk to the health of workers we used publicly available data from Eurostat to define the 
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number enterprises operating in different sectors, the number of workers employed in 
those enterprises, the distribution of enterprises in the EU, and financial measures such 
as turnover, personnel costs and research and development expenditure. 
 
Estimates were made of: 
• the number of firms needing to apply RMMs and the estimated cost of the RMMs 
over the same time period as health benefits (2010-69); 
• the cost of the administrative burden of implementing the OEL (e.g. the cost of 
monitoring and audit); 
• the potential effect on the market for the substance by the imposition of the OEL. 
 
The final analysis comprised a comparison of the costs and benefits of the “do nothing” 
or “business as usual” situation with the scenario in which the possible OEL is added to 
the Directive.  
 
Results  
The 25 substances considered are listed in Table 1 with the IARC and EU carcinogen 
classifications.  Twelve of the substances considered were definite human carcinogens 
(International Agency for Research on Cancer, Group 1), four were probable human 
carcinogens (IARC 2a) and nine were possible human carcinogens (IARC 2b).  There are 
more than ten different types of cancer that may be caused by exposure to these 
substances, most commonly lung and bladder cancer (Table 1). For some of these 
tumour types survival is good, e.g. non-melanoma skin cancer that may be caused by 
mineral oils as used engine oil or benzo[a]pyrene, although for most of the cancers the 
prognosis is relatively poor.  
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Details of the OELs evaluated are also shown in Table 1 along with estimates for the 
percentage of EU workers currently exposed above the limit.  The OEL values for five 
substances were suggested by the European Commission: hard wood dust, vinyl 
chloride monomer, hexavalent chromium, respirable crystalline silica and 1,3 Butadiene. 
All others were selected as “typical” of existing OEL values amongst EU member states 
(note that the OEL for DEE was from Austria, as this was the only one available). For 
some OEL values there is a relatively large proportion of workers judged to be currently 
exposed above the limit, e.g. 75% of workers exposed above a possible hydrazine limit 
of 0.013 mg/m3.  For 14 substance-OEL combinations, including DEE, there are less than 
1% of workers currently exposed above the suggested limit value representing nearly 
full compliance; for these there is little or no health benefit from introducing an OEL at 
that value.  
 
The estimated number of workers currently exposed in the EU ranges from under 1,000 
for bromoethylene to over 7 million for benzo[a]pyrene (Figure 1). There is very little or 
no information on the number of workers who are be exposed to 4,4’-
methylenedianiline (MDA), although there are probably more than about 400,000 
handling this substance. The number exposed to hexachlorobenzene is unknown, as, 
although use of this substance is banned in the EU, some exposure is thought to occur as 
a by-product of a small number of processes. 
 
For two substances (ethylene oxide, bromoethylene) there were no deaths predicted 
from past or future exposures.  No baseline health impact was made for five substances 
because there was insufficient epidemiological evidence (1,2-dichloroethane, 1,2-
dibromoethane, hexachlorobenzene and 2-nitropropane) or exposure data (4, 4' 
methylenedianiline – MDA) to carry out these assessments. The results for cancer 
mortality and cancer incidence for the remaining 18 carcinogens (with rubber dust and 
fume presented separately) are given in Table 2 for the baseline year (2010) and for the 
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predicted period 2010-2069 under the baseline assessment, i.e. assuming ‘do’ nothing, 
together with estimated numbers of cancer cases prevented by introducing an OEL at 
specified values and health and compliance costs.  
 
Table 2 shows that for nine substances it was estimated there would be more than 1,000 
cancer deaths occurring in the EU over the next 60 years if no action is taken; total 
estimated attributable cancer deaths from these nine substances over this period were 
in excess of 700,000. The greatest numbers of excess incident cancers were predicted 
for respirable crystalline silica, diesel engine exhaust and mineral oils as used engine 
oils. The predicted number of future cancer deaths is broadly related to the estimated 
number of workers currently exposed (Figure 2).  
 
There are only seven substances or mixtures where the data suggests a clear health 
benefit in terms of avoided cancer cases over the next 60 years from introducing an OEL 
at the specified values. The largest benefits arise from the introduction of OELs for 
respirable crystalline silica, hardwood dust, hexavalent chromium and rubber fume. The 
highest percentage reduction in incident cases was for the OEL for rubber fume (39%), 
followed by hardwood dust at 1 mg/m3 (28%) and respirable crystalline silica at 0.05 
mg/m3 (23%). For 26 of the 36 substance-OEL combinations where a health assessment 
was possible, there were minimal health benefits from the introduction of an OEL at the 
proposed level, i.e. less than 20 cancer cases avoided over the next 60 years.  
 
Generally, where more than 1,000 cancers were predicted to occur over the coming 60 
years, the baseline health costs were estimated to be above €1,000 million. The two 
largest estimated health baseline costs were for respirable crystalline silica (between 
€190,000,000 and €490,000,000 million) and diesel engine exhaust (€99,000 to 
€260,000 million).   
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Estimated compliance costs ranged from zero to over €100,000 million over the next 60 
years. It was judged that for 14 substance-OEL combinations the compliance cost could 
exceed €1,000 million. Highest costs were for hexavalent chromium, respirable 
crystalline silica, MDA along with beryllium and beryllium compounds. Four substance-
OEL combinations were judged as likely to have a substantial negative impact on small 
and medium size enterprises (respirable crystalline silica – for two of the limits 
evaluated, beryllium and hard wood dust) and in a further six cases it is possible there 
could be a substantial negative impact on SMEs from introducing a proposed OEL.  
 
The monetized health benefits from introducing an OEL were greatest for respirable 
crystalline silica (between €21,000 and €74,000 million, depending on the OEL and the 
uncertainties involved in the estimation). Health benefits were also large for the 
introduction of OELs for hexavalent chromium (around €500 - €1,300 million for a limit 
of 0.025 mg/m3) and rubber process fume (€580 - €1,200 million).  
 
The monetized benefit-to-cost ratio was less than one in all substance-OEL 
combinations except for respirable crystalline silica (all three potential OEL values 
exceeded one, showing a net estimated benefit from introducing an OEL), rubber 
process fume and trichloroethylene (50 mg/m3).  This provides an indication that the 
costs of intervention may be less than the benefits, although it should be noted that 
these comparisons are strongly dependent on the rate used for discounting of future 
costs and benefits, because the majority of the compliance costs occur at the outset 
whereas the majority of the benefits occur in the future. For each substance we carried 
out a sensitivity analysis to assess the impact of discounting on the monetised benefits. 
For example, for wood dust for an OEL of 1 mg/m3 the total health benefit without 
discounting was €333m - €1,600m, which reduced to €51m - €252m with discounting. 
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Similar reductions were seen for other substances; full details are provided in the 
individual substance reports which are available online. 
 
Discussion  
As part of the effort to reduce occupational cancers we have undertaken a 
socioeconomic and health analysis to assess the potential impact of introducing legally 
binding OELs or reducing those already existing for 25 workplace carcinogens. When 
evaluating these results and making recommendations for action we have used a 
pragmatic weight of evidence approach including taking into account: the numbers of 
workers currently exposed across the EU and the exposure levels, the numbers of 
predicted deaths and newly occurring cancers if no action is taken, the size of the risks 
associated with the cancers of concern, the costs to health and to industry and the cost-
benefit ratios.  The detailed evidence for our evaluations is summarized for each 
substance in the online supplementary material (Weight of evidence arguments for 
prioritizing substances for binding OELs). 
 
The cost-benefit ratio together with predicted numbers of deaths as a result of inaction 
suggests that the strongest cases for the introduction of an OEL are for: respirable 
crystalline silica, hexavalent chromium and hardwood dust. Other substances where the 
weight of evidence (for example, high risk estimates, high health burden with no action 
or many workers currently exposed) supports the introduction of a limit include: diesel 
engine exhaust emissions, rubber fume/dust, benzo[a]pyrene, trichloroethylene, 
hydrazine, epichlorohydrin, o-toluidine, mineral oils as used engine oil and MDA.  It 
should be noted that our health impact assessment considered only cancers as the 
endpoint. However, introducing limits for the above substances could also contribute to 
reductions in other health-related conditions such as non-malignant respiratory and 
skin disease. For many of the substances there are therefore likely to be substantial 
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additional baseline health costs and further unquantified health benefits from 
introducing an OEL.  
 
In undertaking this type of exercise there are always many uncertainties. Assumptions 
made in our methodology along with uncertainties and inaccuracies in the data we have 
used may have introduced biases into our estimates, the impact of which is not fully 
captured in the data presented and may result in over or underestimates of the impacts. 
Potential sources of bias include inappropriate choice of risk estimates, imprecision in 
estimates of proportions exposed, inaccurate risk exposure periods, assumptions about 
the decline in exposures, the effectiveness of risk management measures already in 
place and the costs and cost-effectiveness of further risk management measures. At the 
request of the European Commission no allowance was made for non-compliance to the 
limits unlike the previous British study (Hutchings & Rushton, 2012b). In reality it is 
unlikely that there will be complete compliance to limits across all 28 Member States.  
 
For some substances the degree of uncertainty was such that it was not possible to 
undertake a full impact assessment, particularly where there was a lack of good 
epidemiological studies from which to derive risk estimates. We generally chose not to 
use the available toxicological data in these circumstances to avoid problems in trying to 
extrapolate hazard and risk information for animals to humans, and the consequent 
very large increase in uncertainty that would have been involved.  
 
Despite the uncertainties, the results presented in this paper have contributed to 
decisions on the merits or otherwise of intervening. The evaluation of the costs and 
benefits of intervening to reduce the risk from workplace carcinogens were provided in 
a number of forms, including qualitative descriptions, quantification of impacts and 
monetary valuation, where possible.  This allows the effects from proposed intervention 
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to be understood on a variety of levels, recognizing, for example, that monetary 
valuation of health risks is a controversial area.  We believe that it is appropriate to take 
a weight of evidence approach to prioritizing substances for interventions. There were a 
very wide range of health impacts predicted if the status quo continued, from very low 
numbers of predicted cancers over the next 60 years for substances such as refractory 
ceramic fibres (60), 1,3 butadiene (160) and vinyl chloride monomer (300) through to 
more than 100,000 cancers over the same period for used mineral oils (130,000), diesel 
engine exhaust (270,000) and respirable crystalline silica (470,000). These impacts 
strongly suggest where interventions are needed.  However, in addition to cost-benefit 
analyses, other considerations, such as absolute risk in relation to what is considered to 
be acceptable risk for occupational exposures will need to be taken into account when 
identifying priorities for regulatory interventions.  For example, for RCF 50 deaths (60 
incident cases) are predicted under the baseline scenario between 2010 and 2069.  
However, it can also be seen from Figure 2 that only about 10,000 workers are currently 
exposed to RCF in Europe.  For comparison, the Health Council of the Netherlands 
identified a prohibitive risk for occupational carcinogens of 4 per 1,000 over a working 
lifetime (Health Council of the Netherlands, 2012).  Although results presented in this 
paper cannot be used to directly compare with lifetime risk estimates, it is clear that for 
RCF and some other substances considered in this paper the risk estimates are close to 
or even over the prohibitive risk limit applied by the Dutch Health Council and other 
limit setting organisations. 
 
The main interventions explored in our analyses were the introduction of binding 
occupational exposure limits, which were broadly chosen to reflect limits that are 
typically currently found within Europe.  It is perhaps surprising that there is often a 
wide disparity between limits in different European countries; for example, hydrazine 
ranges from 0.013 mg/m3 in Denmark to 0.13 mg/m3 in Spain, both as 8-hour average 
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values.  There were only three substances where the lowest limit tested had an 
important impact, and even in these cases the reduction in the total number of predicted 
cancer deaths was modest: respirable crystalline silica 23%, hard wood dust 28% and 
rubber fume 39%. For substances such as diesel engine exhaust, the limit would need to 
be substantially lower than the “typical” value tested (0.1 mg/m3, as elemental carbon) 
to have any real impact, and probably closer to 0.01 mg/m3. 
 
The costs of compliance were very variable. For many substances the estimated costs 
over the 60 years studied were essentially zero because the exposures were currently 
below the proposed limit.  However, for 14 substance-OEL pairs the compliance costs 
were estimated as probably more than €1,000m; costs were particularly high for 
hexavalent chromium, respirable crystalline silica and beryllium and its compounds.  
Whilst these figures are small in terms of the overall sums of money invested in Europe, 
in some cases it was considered likely that SMEs would bear the main costs and this 
could have a serious detrimental effect on their viability.  
 
For only three of the substances considered was there a positive monetized benefit to 
cost ratio, which reflects the discounting of future costs, and the long time lag between 
intervening and the realisation of the benefits. While it is standard economic practice to 
make these adjustments we consider it unwise to rely on this one measure of the 
effectiveness of any planned policy changes. We have therefore tried to use a weight of 
evidence approach highlighting the various pieces of evidence, such as the number of 
lives lost from inaction and the potential of interventions to prevent future deaths, along 
with the costs of intervening.  In this way we consider a more balanced view of the 
benefits or otherwise of intervening can be obtained.  
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The research has highlighted the limited information available on the hazards, risks and 
risk management measures in place for many of the substances assessed. We consider 
that it would be of substantial benefit to be increasingly more proactive in the future in 
collecting information about occupational carcinogens in the EU. Priority, in particular, 
should be given to collect better information about MDA and mineral oil as used engine 
oil, where the potential health impacts are large and the uncertainties are greatest. 
However, we consider that it is appropriate for the EU to support the development of a 
surveillance system to collect data on the prevalence and level of exposure to the 
occupational carcinogens causing the greatest health burden.  
 
Burden of disease measures, such as the attributable fraction, which indicates the 
proportion of a disease attributable to a specific exposure, and the associated numbers 
such as attributable deaths or newly occurring cancers and DALYs, are now widely 
accepted measures of burden of disease and are increasingly used to facilitate 
identification of major risk factors and high risk populations, support decisions on 
priority actions for risk reduction and provide an understanding of important 
contributions to health inequalities. Our study has extended this to provide additional 
measures including estimation of direct and indirect costs of the treatment and the costs 
of less tangible effects such as disfigurement, anxiety etc. The comparison of these with 
the costs of appropriate intervention strategies allows decision makers to include cost-
benefit comparisons as part of their risk reduction plans. This study has demonstrated 
that a range of measures can be systematically evaluated to aid decision making by the 
European Commission and social partners.  
 
The results together with other evidence from, for example the European Scientific 
Committee on Occupational Exposure Limits (SCOEL), have been used in the review of 
the Carcinogens Directive with the EU Advisory Committee on Safety and Health via the 
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Working Party on Chemicals, in consultation with industry stakeholders, and social 
partners. The work has formed the basis of the Impact Assessment completed by the 
European Commission in advance of legislative change 
(ec.europa.eu/social/BlobServlet?docId=15541&langId=en). Setting binding limit 
values under the Carcinogens Directive could have an important impact on the number 
of workers in Europe who suffer from work related cancers. However, even if all the 
actions evaluated here were introduced there would still be a substantial number of 
work-related cancers occurring in the future. Further action will be necessary to 
address this residual risk. One alternative approach that could be considered is to build 
social partnerships between employers and workers to introduce a culture of 
continuous improvement in working conditions throughout an industry rather than 
focussing on minimum standards as is the case with setting binding limit values 
(Cherrie, 2017).  
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Titles and legends to figures 
 
Figure 1:  Number of workers exposed over the risk exposure period by carcinogen 
 
Figure 2:   Baseline health impact (mortality) in 2010 versus number of workers exposed  
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Table 1  Substances and cancer sites evaluated   
 
Substance or mixture EU carcinogen 
Classification 
IARC 
Classification 
Cancer Sites OEL Values Evaluated 
(mg/m3) and estimated 
percentage of workers 
currently exposed above 
value 
1, 3 Butadiene 1a 1 Lymphohaematopoietic 1.14 
(46%) 
2.28 
(28%) 
11.4 
(4%) 
Benzo[a]pyrene 1b 1 Bladder, Lung  
Non-melanoma skin cancer 
0.002 
(0%) 
  
Beryllium and 
beryllium compounds,  
as Be 
1b 1 Lung 0.002 
(10%) 
  
Hexavalent chromium 1b 1 Lung, Sinonasal 0.025 
(8%) 
0.05 
(4%) 
0.1 
(2%) 
Ethylene oxide 1b 1 Leukaemia 1.8 
(0%) 
  
Hard wood dust, as 
inhalable dust # 
NA 1 Nasopharyngeal, Sinonasal 1(8%) 5    
(1%) 
 
Mineral oils, as used 
engine oil ∞ 
NA 1 Non-melanoma skin cancer NA   
o-Toluidine 1b 1 Bladder 0.4 
(2%) 
4.4 
(0%) 
 
Respirable crystalline 
silica 
NA 1 Lung 0.05 
(41%) 
0.1 
(26%) 
0.2 
(14%) 
Rubber process dust ? NA 1 Larynx, Leukaemia, Lung, 
Stomach 
6 (14%)   
Rubber process fume ? NA 1 Larynx, Leukaemia, Lung, 
Stomach 
0.6 
(37%) 
  
Vinyl chloride 
monomer (VCM) 
1a 1 Liver 2.56 
(4%) 
5.11 
(2%) 
7.67 
(1%) 
Diesel engine exhaust 
emissions (DEE) § 
NA 1 Bladder, Lung 0.1 
(1%) 
  
1-Chloro-2, 3-
epoxypropane 
1b 2a Central Nervous System, 
Lung 
1.9 
(0%) 
  
4,4'-methylene bis 2-
chloroaniline 
(MbOCA) † 
1b 2a Bladder 5 (NK) 15 (NK)  
Acrylamide 1b 2a Pancreas 0.03 
(10%) 
  
Bromoethylene 1b 2a Liver 22 (0%)   
Trichloroethylene 1b 2a Kidney, Liver, Non-Hodgkin 
Lymphoma 
50 
(28%) 
273 
(2%) 
 
1, 2-Dibromoethane 1b 2b Inadequate human 0.8   
evidence (8%) 
1, 2-Dichloroethane 1b 2b Inadequate human 
evidence 
4 (13%) 20 
(<1%) 
 
1, 2-Epoxypropane 1b 2b Leukaemia 4.8 
(<1%) 
12 
(<1%) 
 
2-Nitropropane 1b 2b Inadequate human 
evidence 
19 (0%)   
4, 4'-
methylenedianiline 
(MDA) 
1b 2b Inadequate human 
evidence 
0.08 
(NK) 
0.8 
(NK) 
 
Hexachlorobenzene 1b 2b Inadequate human 
evidence 
0.002 
(0%) 
0.025 
(0%) 
 
Hydrazine 1b 2b Colorectal, Lung 0.013 
(75%) 
0.13 
(8%) 
 
Refractory ceramic 
fibres (RCF) ‡ 
1b 2b Lung 0.1 
(50%) 
1 (10%)  
 
#   a separate report is available reviewing methods of measuring inhalable hard wood dust 
★ rubber process dust and fume – both measured as the inhalable aerosol fraction. Fume is the rubber fume 
as cyclohexane-soluble fraction of the dust.   These were evaluated separately in the project.  
§   measured as elemental carbon 
†   units for MbOCA are μmol/mol in urine sample    
‡   units for RCF are fibres/ml 
∞  risks to skin from dermal contact  - setting an OEL was considered inappropriate 
NK   not known 
NA   not applicable 
Table 2  Estimated incident cancers and cancer deaths at baseline, predicted cancers under the baseline scenario, predicted cancers 
prevented by introducing an OEL, and health and compliance costs 2010 to 2069 
 
Substance or 
mixture 
Baseline 
incident 
cancers 
2010 
 Predicted 
incident 
cancers      
2010 – 
2069 
under 
baseline 
scenario   
Baseline 
Deaths 
2010 
Predicted 
Deaths 
2010 – 
2069 under 
baseline 
scenario 
OEL value     
(mg/m3, 
unless stated 
otherwise) 
Predicted 
avoided 
incident 
cancers 
2010-2069 
from 
implementi
ng the OEL 
% 
decrease 
in health 
risk Total compliance costs 
(€m) 
Total health 
benefits (€m) 
Benefit to 
cost ratio§ 
Respirable 
crystalline silica 
7,600 470,000 6,900 440,000 0.2 80,000 17% 10,000 21,000 - 56,000 2.3 – 5.4 
        0.1 99,000 21% 19,000 26,000 - 68,000 1.5 – 3.5 
      0.05 110,000 23% 34,000 28,000 - 74,000 0.9 – 2.1 
Diesel engine 
exhaust emissions 
5,700 270,000 4,600 230,000 0.1 0 0 25 - 250 0 0
Mineral oils as used 
engine oil 
900 130,000 7 1,200 NA Not assessed 46-920 Not assessed -
Benzo[a]pyrene:  
- Lung & Bladder 
- NMSC 
 
600 
250 
 
13,000 
18,000 
480 
2 
10,000 
160 
0.002 0 0 0 0 0
Hexavalent 
chromium 
490 24,000 380 17,000 0.1 600 2.5% 9,000 - 37,000 159 - 456 0.006 – 0.03 
   0.05 1,400 5.8% 18,000 - 67,000 340 - 991 0.007 – 0.03 
   0.025 1,800 7.5% 30,000 - 115,000 461 - 1,327 0.006 – 0.03 
Hard wood dust 450 14,000 200 6,300 3 500 3.6% 0 11 - 51 0
   1 3,900 28% 3,800 - 8,600 61 - 297 0.01 – 0.05
Hydrazine 149 2,500 43 710 0.13
0.013 
0
0 
0
0 
15-47
62-200 
0
0 
0
Trichloroethylene 93 4,800 59 3,300 273 10 0.2% 61 0 0
   50 580 12% 428 120 - 430 0.3 – 1.0
Rubber process 
fume 
61 3,600 39 2,500 0.6 1,400 39% 470 - 3,200 580 - 1,200 0.25 – 1.5
1-Chloro-2,3-
epoxypropane  
34 2,600 31 2,400 1.9 0 0 0 0 0
o-Toluidine 22 490 7 150 4.4
0.4 
0
 
0 0 0 0
Rubber process 
dust 
17 710 11 490 6 20 2.8% 55 - 280 24 - 46 0.1 – 0.5
Vinyl chloride 
monomer 
14 300 14 300 7.67
5.11 
2.56 
0
0 
0 
0
0 
0 
0
3-30 
40-185 
0
0 
1-3 
0
0 
0.008 – 0.05 
4,4'-Methylene bis 
2-chloroaniline   
(MbOCA) 
8 280 3 100 15µmol/mol
5µmol/mol 
<1
20 
0% 560 - 1,100 1 - 7 0.001 – 0.009 
Acrylamide 7 250 6 230 0.03 50 20% 160 - 330 0 0
Beryllium and 
beryllium 
compounds 
6 390 6 390 0.002 50
 
7.1% 1,500 - 3,000 1 - 11 0.001 – 0.005 
Refractory ceramic 
fibres 
2 60 2 50 1fibres/ml
0.1fibres/ml 
0 0 0
60 - 2,500 
1 – 2
1 - 2 
0
0.0005 – 
0.004 
1, 3 Butadiene 2 160 1 100 11.4
2.28 
1.14 
0
0 
0 
0
0 
0 
2 - 7
17 – 63 
27 - 100 
0
0 
0 
0
0 
0 
1, 2-Epoxypropane 0 0 0 0 12 0 0 0 0 0
   4.8
 
§     The 5th and 95th percentile points of a Monte Carlo simulation of the ratio of values drawn from the underlying cost ranges. 
  
 
